Authors : Shivam Yadav; Devesh Shahu; Mona Salwatkar

Volume/Issue : Volume 10 - 2025, Issue 3 - March

Google Scholar : https://tinyurl.com/mpb85rsm

Scribd : https://tinyurl.com/2rjv72u8

DOI : https://doi.org/10.38124/ijisrt/25mar132

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : The main aim of this study is to get information about the effect of Salvia miltiorrhiza (Red Sage Root) on the bone mineral density (BMD) affected from osteoporosis, and effectivity of ectosteric tanshinones CatK inhibitor isolated from Salvia miltiorrhiza blocked, selectively, the collagenase activity of CatK, without affecting the active site and confirmed its bone-preserving activity. Objective: The objective of this study is to develop a safe and effective herbal formulation using Salvia miltiorrhiza (red sage) for the treatment of osteoporosis, focusing on maximizing therapeutic benefits while minimizing side effects. The formulation aims to leverage the natural properties of red sage, known for its anti-inflammatory, antioxidant, and bone-regenerative properties, to promote bone health and improve bone density. Methodology: This study focuses on the development and evaluation of a complex herbal formulation using Salvia miltiorrhiza (red sage) targeted for osteoporosis treatment, with an emphasis on safety and minimal side effects, it involves the following Steps; Extraction Process, Preliminary Phytochemical Screening, Isolation of Extract, Invitro Studies, Invivo Studies & Formulation of solid Dosage form (Lep). Conclusion: Apart from dietary medications and chemical enriched medicines, herb Salvia miltiorrhiza has been found of great importance in curing osteoporosis by improving bone mineral density by 35 percent, without any side-effects.

Keywords : Salvia miltiorrhiza; Herbal Cat K Inhibitor, Anti-Osteoporotic Agent, Bone Mineral Density Retention.

References :

1. Dwivedi, S., & Dwivedi, A. (2007). Formulation and evaluation of herbal gels containing essential oils and extracts for antimicrobial activity. International Journal of Pharmaceutical Sciences.
2. Garg, S., Sharma, L., & Dalal, H. (2021). Role of Diet and Salvia miltiorrhiza to Manage Osteoporosis. Indo Global Journal of Pharmaceutical Sciences, 11(01), 42–46.
3. Guo, Y., Li, Y., Xue, L., Severino, R. P., Gao, S., Niu, J., Qin, L.-P., Zhang, D., & Brömme, D. (2014). Salvia miltiorrhiza: An ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. Journal of Ethnopharmacology, 155(3), 1401–1416.
4. Leung, P., Pickarski, M., Zhuo, Y., Masarachia, P. J., & Duong, L. T. (2011). The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone, 49(4), 623–635.
5. Panwar, P., Law, S., Jamroz, A., Azizi, P., Zhang, D., Ciufolini, M., & Brömme, D. (2018). Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone. British Journal of Pharmacology, 175(6), 902–923.
6. Park, B., Song, H. S., Kwon, J. E., Cho, S. M., Jang, S.-A., Kim, M. Y., & Kang, S. C. (2017). Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice. BMC Complementary and Alternative Medicine, 17(1), 545.
7. Smith, J., Brown, T., & Wang, Y. (2020). Advances in osteoporosis management: A review of current therapies and future prospects. Journal of Bone Research, 12(3), 123-134.
8. Wang, Lili, Shan Wang, Xuan Dai, Gaiyue Yue, Jiyuan Yin, Tianshu Xu, Hanfen Shi, Tianyuan Liu, Zhanhong Jia, Dieter Brömme, Shuofeng Zhang, and Dongwei Zhang. 2024. “Salvia miltiorrhiza in Osteoporosis: A Review of Its Phytochemistry, Traditional Clinical Uses and Preclinical Studies (2014–2024).” Frontiers in Pharmacology 15:1483431.
9. Wang, Q., Zhao, H., & Liu, J. (2021). Therapeutic potential of Tanshinones in osteoporosis: A comprehensive review. Current Medicinal Chemistry, 28(15), 2960-2975.
10. Zhou, X., Lin, Z., & Yin, J. (2019). Role of Tanshinone VI in inhibiting osteoclastogenesis through RANKL-mediated pathways. Journal of Bone Metabolism, 26(4), 201-210.